Jinliang Liu

Dr. Jinliang Liu

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2019 in Advanced Science
Verified
Journal Article
Open access
PDF file
XZXiaohui Zhu
Xiaohui Zhu
JZJing Zhang
Jing Zhang
Jinliang LiuJinliang Liu
Jinliang Liu
YZYong Zhang
Yong Zhang
Upconversion is a nonlinear optical phenomenon that involves the emission of high‐energy photons by sequential absorption of two or more low‐energy excitation photons. Due to their excellent physiochemical properties such as deep penetration depth, little damage to samples, and high chemical stability, upconversion nanoparticles (UCNPs) are extensively applied in bioimaging, biosensing, theranostic, and photochemical reactions. Here, recent achievements in the synthesis, optimization, and applications of UCNP‐based nanomaterials are reviewed. The state‐of‐the‐art approaches to synthesize UCNPs in the past few years are introduced first, followed by a summary of several strategies to optimize upconversion emissive properties and various applications of UCNPs. Lastly, the challenges and future perspectives of UCNPs are provided as a conclusion.

17 February 2022 in Microchimica Acta
Verified
Journal Article
Closed access
PDF file
YLYong Li
Yong Li
CCChen Chen
Chen Chen
FLFangfang Liu
Fangfang Liu
Jinliang LiuJinliang Liu
Jinliang Liu

1 January 2019 in Theranostics
Verified
Journal Article
Open access
JWJiaxin Wang
Jiaxin Wang
CYChenjie Yao
Chenjie Yao
BSBin Shen
Bin Shen
XZXiaohui Zhu
Xiaohui Zhu
YLYong Li
Yong Li
LSLining Sun
Lining Sun
Nanoparticle-based theranostics combines tumor imaging and cancer therapy in one platform, but the synthesis of theranostic agents is impeded by chemical groups on the surface and the size and morphology of the components. Strategies to construct a multifunctional platform for bioimaging and photothermal therapy (PTT) are urgently needed. A new upconversion-magnetic agent (FeCUPs) based on hollow carbon spheres, which is both a photothermal agent and a dual carrier of luminescent and magnetic nanoparticles, provides an effective approach for tumor elimination.

9 March 2022 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
CWChangsong Wu
Changsong Wu
MCMeihui Cui
Meihui Cui
LCLi Cai
Li Cai
CCChen Chen
Chen Chen
XZXiaohui Zhu
Xiaohui Zhu
YZYong Zhang
Yong Zhang

26 January 2021 in Analytical Chemistry
Verified
Journal Article
Closed access
XGXinran Guo
Xinran Guo
YYYun Yuan
Yun Yuan
Jinliang LiuJinliang Liu
Jinliang Liu
SFShuai Fu
Shuai Fu
JZJing Zhang
Jing Zhang
YZYong Zhang
Yong Zhang

30 December 2021 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
QWQin Wei
Qin Wei
YWYihan Wu
Yihan Wu
FLFangfang Liu
Fangfang Liu
JCJiao Cao
Jiao Cao
Jinliang LiuJinliang Liu
Jinliang Liu
Nanoscale metal–organic frameworks (MOFs) have attracted widespread interest due to their unique properties including a tunable porous structure, high drug loading capacity, structural diversity, and outstanding biocompatibility. MOFs have been extensively explored as drug nanocarriers in biotherapeutics. However, by harnessing the functionality of ligands and metal ions or clusters in MOFs, the applications of MOFs can be extended beyond drug delivery vehicles. Based on the intrinsic properties of the components of MOFs (e.g. magnetic moments of metal ions and fluorescence of ligands), different imaging modes can be achieved with varied MOFs. With careful design of the composition of MOFs (e.g. modification of organic linkers), they can respond to tumor microenvironments to realize on-demand treatment. By incorporating porphyrin-based ligands (photosensitizers for photodynamic therapy) or high-Z metal ions (radiosensitizers for radiotherapy) into the scaffold of MOFs, MOFs themselves can act as anticancer therapeutic agents. In this review, we highlight the application of MOFs from the above-mentioned aspects and discuss the prospects and challenges for using MOFs in stimuli-responsive imaging-guided antitumor therapy.